Jump to a section
Daily tesamorelin dosage
The daily amount depends on the formulation: 1.28 mg for EGRIFTA WR or 1.4 mg for EGRIFTA SV, injected once a day. The original EGRIFTA formulation used in the pivotal trials delivered 2 mg daily. Those numbers describe different formulations, not a starting, intermediate and advanced dose. [1] [2]
- Labeled concentration
- 8 mg/mL
- Volume per dose
- 0.16 mL
- Frequency
- Once every day
- Labeled concentration
- 4 mg/mL
- Volume per dose
- 0.35 mL
- Frequency
- Once every day
Approved regimens for adults with HIV-associated lipodystrophy. WR and SV are not substitutable. These directions do not establish a dose for the separate research vial or pen. [1] [2]
A 10 mg vial is the container total. It does not tell you the amount per injection, how often to inject or how long to continue. The supplied 10 mg research vial and 10 mg pen are different products from the EGRIFTA formulations above. Their product records do not establish equivalent absorption or a medical dosing schedule. [4]
Dose by body weight, sex and training goal
The adult EGRIFTA labels use fixed amounts, with no kilogram-based formula, loading phase or separate dose for women. A higher body weight or a harder training program does not supply a reason to multiply the amount. Changing a dose also changes exposure to the glucose, fluid-retention and IGF-1 effects described in the side-effects article. [1]
Reconstituting a 10 mg tesamorelin vial
10 mg in 2 mL of final solution gives 5 mg/mL. At that concentration, 2 mg occupies 0.4 mL, or 40 units on a U-100 syringe. Adding more liquid reduces the concentration; it does not add tesamorelin.
Concentration example for the 10 mg research vial. A validated diluent, mixing volume and post-mixing use period have not been supplied. The 2 mL example is not a preparation prescription. [4]
Confirm the 10 mg vial
Check the ingredient, total amount, intact seal and batch identifier. A pen is already in solution and does not belong in this mixing calculation.
Confirm the liquid
The product-specific preparation method must identify a compatible diluent. A 10 mg label alone cannot select bacteriostatic water or sterile water.
Keep preparation clean
Use a clean work area and fresh sterile transfer equipment for an injectable medicine. Do not return a used needle or syringe to a vial. [5]
Add slowly
The powder handling sheet specifies slow addition against the vial wall and no shaking. It does not supply the missing diluent or volume. [4]
Record the final volume
Write down the concentration and preparation date. Use the final mixed volume in the calculator if it differs from the amount of liquid added.
Use the correct storage
Prepared vial material: 2–8°C (36–46°F), protected from light. Sealed powder: −20°C (−4°F), dry and dark. Storage temperature does not establish an expiry after mixing. [4]
EGRIFTA WR and SV have their own mixing instructions
| Formulation | Preparation | After mixing |
|---|---|---|
| WR · 11.6 mg vial | 1.3 mL of the supplied bacteriostatic diluent; swirl gently. Labeled final concentration: 8 mg/mL. | Seven consecutive daily doses. Store at 20–25°C (68–77°F); discard unused solution seven days after mixing. Do not freeze. |
| SV · 2 mg vial | 0.5 mL of the supplied sterile water; gently roll for 30 seconds. Final concentration: 4 mg/mL. | Use immediately and discard the remainder. Do not refrigerate or freeze the mixed solution. |
Formulation-specific FDA instructions. WR's 1.3 mL is the added diluent; use its labeled 8 mg/mL concentration, not 11.6 ÷ 1.3. Neither row supplies handling directions for a different 10 mg research vial. [1] [2]
Abdominal injection sites
Prescribed EGRIFTA is injected into the fatty tissue beneath the abdominal skin, at least 2 inches (5 cm) from the belly button. Move to a different spot with each dose. Avoid scars, bruises, irritated skin and hard bumps left by earlier injections. [1] [3]
Use abdominal fatty tissue
EGRIFTA is injected under the skin of the abdomen. The medicine's instructions specify this area.
Keep clear of the belly button
Leave at least 2 inches (about 5 cm) between the injection spot and the navel.
Change spots each day
Rotate within the abdomen. Avoid bruises, scars and irritated skin.
The labeled route is subcutaneous, not into an abdominal muscle. Tesamorelin stimulates growth-hormone release through the pituitary; the needle does not select the fat immediately underneath it for removal. Have the dispensing team demonstrate the technique and the exact device before the first prescribed dose. [1]
Morning or evening, food and days off
Keep a consistent daily time
The instructions specify once daily. They do not require a morning or bedtime injection. MedlinePlus advises using approximately the same time each day. [3]
No specified fasting window
The FDA instructions do not require an empty stomach or a set gap after meals. MedlinePlus advises continuing the normal diet unless the clinician directs otherwise. [3]
Do not double a missed prescription dose. MedlinePlus advises taking it when remembered unless the next dose is close; in that case, skip the missed dose and return to the regular schedule. It does not define a universal number of hours for every situation. [3]
Tesamorelin dosage calculator: mg, mL and U-100 units
Enter your target amount first, then set the vial total and final mixed volume. The loaded example uses 10 mg / 2 mL / 2,000 mcg and calculates 40 units, or 0.4 mL.
Loaded with 10 mg vial / 2 mL
Tesamorelin amount per calculation.
Use the final mixed volume if it differs from the water added. The loaded values are a calculation example.
on a U-100 syringe
Vial arithmetic only. Not a dose recommendation.
Calculation ready.
Portions exclude transfer losses, priming and discard limits.
U-100 units measure liquid volume, not hormone potency. One unit is 0.01 mL on that syringe scale. At 5 mg/mL, 10 units contains 0.5 mg; at 10 mg/mL, the same 10 units contains 1 mg. An “IU of growth hormone” is a different measurement.
The calculator uses the entered final volume. Do not substitute the amount of added diluent when a product gives a different final concentration. Pen dial marks also need their own verified calibration; the syringe result is not a click setting.
Daily and weekly tesamorelin totals
| Regimen and formulation | Per day | Per week | 28 days |
|---|---|---|---|
| EGRIFTA WR | 1.28 mg | 8.96 mg | 35.84 mg |
| EGRIFTA SV | 1.4 mg | 9.8 mg | 39.2 mg |
| Original EGRIFTA trial regimen | 2 mg | 14 mg | 56 mg |
Arithmetic from the stated daily regimens. Different formulations have different absorption and preparation; this is not a dose-equivalence ladder. Vial counts also depend on labeled single-use or seven-day discard rules. [1] [2]
For any other documented schedule, multiply the amount per administration by the actual number of administrations. At 2 mg per administration, five weekly injections would total 10 mg; seven would total 14 mg. Taking a second 2 mg injection on the same day doubles that day's amount.
Tesamorelin cycle length and time off
The pivotal fat-reduction studies evaluated 26 weeks of daily treatment, with an extension to 52 weeks. An eight- or twelve-week course is a shorter exposure than that main trial period. It cannot promise the same result on an accelerated timetable. [1]
Main fat-reduction endpoint
CT measurements assessed the change in visceral fat in adults with HIV-associated lipodystrophy.
Continued treatment
The extension assessed persistence of the effect with continued daily use.
Visceral fat can return
Switching to placebo after week 26 was followed by regained visceral fat. A finished course did not make the reduction permanent.
Clinical-trial time points, not a recommended bodybuilding cycle. [1] Tesamorelin results and the stopping-treatment data →
Continuation depends on the actual response and blood results. The FDA label calls for glucose assessment before treatment and monitoring during treatment, plus IGF-1 monitoring. Persistent marked IGF-1 elevation or worsening glucose without clear benefit can change the decision to continue. It does not supply a universal laboratory timetable or a scheduled “reset” month. [1]
A short plasma half-life does not justify repeated daily injections. WR's measured mean half-life after a 1.28 mg subcutaneous dose was 11 minutes in healthy subjects, while its prescribed schedule remains once daily. The downstream hormonal response lasts on a different timescale from the peptide's presence in blood. [1]
Tesamorelin pen concentration and volume
The supplied pen contains 10 mg in 3 mL: approximately 3.33 mg/mL. It is already in solution, with 0.9% benzyl alcohol in the bacteriostatic-water vehicle. The nominal total is the same as the 10 mg powder vial, but the liquid concentration is fixed. [4]
0.6 mL is a volume calculation, not a pen setting. A verified volume per click has not been provided. The pen's 3 mL capacity cannot establish how many dial clicks deliver a particular amount. Keep it at 2–8°C (36–46°F), protected from light, and do not freeze it. An in-use lifespan has not been supplied. [4] Pen details and product comparison →
Total milligrams, vials and pens per course
At an entered amount of 2 mg, a nominal 10 mg container holds five mathematical portions. The table applies that amount to different durations so the total quantity is explicit.
| Duration | Calculation | Total | 10 mg containers |
|---|---|---|---|
| 4 weeks | 2 mg × 28 days | 56 mg | 6 |
| 8 weeks | 2 mg × 56 days | 112 mg | 12 |
| 12 weeks | 2 mg × 84 days | 168 mg | 17 |
Whole containers rounded up. These are arithmetic examples for the listed 10 mg formats, not prescribed courses. Transfer losses, pen priming, residual liquid and actual discard limits reduce usable quantity.
For branded EGRIFTA, count the labeled doses: a 28-day WR supply uses four weekly vials; 28 days of SV uses 28 single-dose vials. Do not divide the total drug in a single-dose vial to invent additional future injections. [1] [2] Compare the supplied Tesamorelin vial and pen →
Questions & answers.
What is the daily tesamorelin dose?
The current EGRIFTA WR label specifies 1.28 mg once daily; EGRIFTA SV specifies 1.4 mg once daily. The original formulation used in pivotal trials delivered 2 mg daily. These are formulation-specific regimens for HIV-associated lipodystrophy, not interchangeable instructions for a research vial or pen.
How many units is 2 mg of tesamorelin?
At 5 mg/mL, 2 mg is 0.4 mL or 40 U-100 units. At 10 mg/mL, it is 0.2 mL or 20 units. You need the actual concentration before a milligram amount can be converted into syringe units.
How much water goes into a 10 mg tesamorelin vial?
The supplied research-vial documents do not specify a validated diluent or mixing volume. As arithmetic, a final volume of 2 mL gives 5 mg/mL and a final volume of 1 mL gives 10 mg/mL. EGRIFTA WR and SV have their own different preparation instructions.
Should tesamorelin be taken at night or on an empty stomach?
The FDA instructions specify once daily without requiring bedtime or a fasting interval. MedlinePlus advises a consistent daily time and the normal diet unless the prescribing clinician directs otherwise.
Where is prescribed tesamorelin injected?
EGRIFTA is injected under the abdominal skin, at least 2 inches or 5 cm from the belly button. Rotate spots and avoid scars, bruises, irritated skin and hard bumps. The dispensing team should demonstrate the technique for the actual product.
Does tesamorelin need to be cycled?
The EGRIFTA labels use continuous daily treatment and do not specify five-days-on schedules or a planned month off. Pivotal studies assessed 26 weeks with extension to 52 weeks. Continued treatment depends on response, glucose, IGF-1 and other individual risks.
How many clicks give 2 mg from the 10 mg Tesamorelin pen?
The 10 mg / 3 mL pen has a nominal concentration of 10/3 mg/mL, so 2 mg corresponds to 0.6 mL. A verified click-to-volume calibration has not been supplied, so that volume cannot be converted into a reliable dial setting.
How long does a 10 mg tesamorelin vial last?
At an entered amount of 2 mg, 10 mg represents five mathematical portions; at 1 mg it represents ten. This does not establish a recommended schedule or how long a mixed vial remains usable. Losses and product-specific discard limits also matter.
Sources & batch documents5 references · expand to read
- FDA: EGRIFTA WR prescribing information, formulation-specific dose, preparation, safety and clinical trials ↗
- FDA: EGRIFTA SV prescribing information, 1.4 mg daily dose and immediate-use preparation ↗
- MedlinePlus: tesamorelin injection, daily timing, food, missed doses and injection-site care ↗
- Supplied Tesamorelin 10 mg vial and 10 mg / 3 mL pen specifications, checked 6 November 2026 ↗
- CDC: injection safety, single-use equipment and the limits of preservatives ↗